NHS
North East and North Cumbria

Our Reference North East and North Cumbria ICB\ FOI ICB 26–284

North East and North Cumbria ICB
Pemberton House
Colima Avenue
Sunderland Enterprise Park
Sunderland
SR5 3XB

Tel: 0191 535 4288
E-mail: nencicb.foi@nhs.net

By Email

15 September 2026

Dear Applicant

Freedom of Information Act 2000 – Request for Information – NHS North East and North Cumbria Integrated Care Board (NENC ICB)

Thank you for your request received on 4 September 2026 for information held by NHS North East and North Cumbria Integrated Care Board (the ICB) under the provisions of the Freedom of Information Act 2000. The ICB covers the areas of County Durham, Newcastle Gateshead, North Cumbria, North Tyneside, Northumberland, South Tyneside, Sunderland, and Tees Valley.

Please find the information you requested on behalf of the ICB as follows.

Your Request

I am requesting the following information in relation to NICE Technology Appraisal TA1152 — Semaglutide for cardiovascular disease risk reduction, published 7 May 2026 with a statutory implementation deadline of 5 August 2026:

1. Has your ICB fully implemented TA1152 and made semaglutide available to all patients meeting the eligibility criteria specified in the appraisal?
   If YES: On what exact date was full implementation completed? Please provide the relevant commissioning policy document or reference number.
   If NO: What is the specific legal basis for not implementing TA1152, given the statutory funding duty set out in Regulation 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013?

2. Has your ICB received any written authorisation, extension, exemption, or alternative implementation arrangement from NICE or NHS England permitting implementation beyond 5 August 2026? If yes, please provide a copy of the document.
3. Does your ICB consider that existing commissioning arrangements for semaglutide under TA875 (weight management) constitute full implementation of TA1152? If yes, please explain

the reasoning and confirm whether all patients meeting TA1152 criteria are being identified and offered treatment regardless of weight or BMI criteria.

4. If not yet implemented: What is the confirmed date for full implementation? What are the specific operational or clinical reasons for the delay?
5. Has your ICB carried out an Equality Impact Assessment in relation to the implementation or delayed implementation of TA1152, in compliance with the Public Sector Equality Duty (Section 149 of the Equality Act 2010)? If yes, please provide a copy.
6. How many patients have been prescribed semaglutide under the specific TA1152 eligibility criteria since 5 August 2026? Please state "0" if none.
7. Please provide copies of all board papers, commissioning policies, internal guidance, or meeting minutes that reference TA1152 or its implementation status.

Our Response

1. The link to the NICE technology appraisal (TA) is: Overview | Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity | Guidance | NICE. As per Northern Treatment Advisory Group (NTAG) we have made Wegovy available for patients in NENC that fit the NICE TA – Formulary entry as below:

Cardiovascular disease

GREEN for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

Solution for injection: 0.25mg/0.37ml, 0.5mg/0.37ml, 1mg/0.75ml, 1.7mg/0.75ml & 2.4mg/0.75ml pre-filled pens (**Wegovy®**)

TA1152 was approved by ICB Exec in Aug 2026 and included in the July 2026 medicines decision summary on the NTAG website. The NTAG decision summary July 2026 is in the table below and the decision document link is https://ntag.nhs.uk/nenc-clinical-effectiveness-and-governance-ceg-subcommittee-and-ntag-decisions-may-and-july-2026-updated/

Drug and indication	Rationale / criteria	Status and formulary position assigned	Notes on decision	Cost impact and commissioning / service implications	Recommendation from NENC CEG
TA1152: Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity 07/05/26 **Commissioning: ICB, tariff included.**	Semaglutide (up to a maintenance dose of 2.4 mg once weekly) can be used, within its marketing authorisation, alongside a reduced-calorie diet and increased physical activity, as an option for reducing the risk of a major adverse cardiovascular event (that is, cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with both: • established cardiovascular disease (CVD), defined as at least 1 of the following: ○ previous myocardial infarction ○ previous ischaemic or haemorrhagic stroke ○ symptomatic peripheral arterial disease (they have intermittent claudication with an ankle-brachial index of less than 0.85 at rest, or have had a peripheral arterial revascularisation procedure or an amputation because of atherosclerotic disease), and • a body mass index (BMI) of at least 27 kg/m^2. Semaglutide can only be used if the company provides it according to the commercial arrangement.	Add to formulary as a GREEN drug for this indication. Wegovy® listed as a RED drug for managing overweight and obesity in line with NICE guidance within a specialist weight management service (including but not limited to tiers 3 and 4).	The key drivers of resource impact and things to note are that: • Semaglutide is used alongside existing drugs for secondary cardiovascular event prevention. • The resource impact template allows any increase in behavioural support appointments to be costed. These appointments were not included in the company's cost-effectiveness modelling. The company thought that the level of healthy lifestyle counselling provided in both arms of the SELECT clinical trial was representative of NHS clinical practice for secondary cardiovascular event prevention. NICE expects 1.2 million people in England to be eligible in year 1, with 31,000 taking up treatment. In NENC the eligible population is 113,183 in year 1 based on NICE costing template with 2173 patients treated in year 1, rising to 7151 patients in year 3 including those still on treatment from years 1 and 2. Semaglutide is subject to a commercial arrangement; cost impacts will be provided to stakeholders separately.		Approved addition to formulary

2. No, the ICB did not receive these arrangements from NHS England. This followed the approved NENC ICB governance process for NICE TAs. It went for 4 weeks NTAG consultation in June 2026 (the month after it was published alongside all the NICE TAs published in the same month (May 2026), the NTAG/ Clinical Effectiveness and Governance (CEG) in July 2026 then because of cost impact it went to the next available ICB Exec meeting which was in Aug 2026.
3. No, Semaglutide is still RED for TA875, but it has been added as GREEN for TA1152.
4. Please refer to the response to question 1; TA1152 has been fully implemented.
5. No ICB Equality Impact Assessment was done. We do not do these for NICE TAs as NICE does one and publishes this on their website.
6. On this occasion it is not possible to provide the requested information. In line with your rights under section 1(1)(a) of the Act to be informed whether information is held, we confirm the ICB does not hold any of the information requested.

   It is not possible to ascertain as Wegovy prescribing could also be for obesity (outside of guidance) and there is also generic semaglutide prescribing which could be for diabetes, etc. All prescribing data is publicly available from the NHS BSA website: Prescribing data | NHSBSA
7. All meeting minutes and decisions are held by NTAG and are publicly available on the NTAG website: https://ntag.nhs.uk/latest_news/

In accordance with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log. Therefore, a version of our response which will protect your anonymity will be posted on the NHS ICB website https://northeastnorthcumbria.nhs.uk/.

If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me on the above telephone number or at the above address.

If you are unhappy with the service you have received in relation to your request and wish to request a review of our decision, you should write to the Information Governance Manager using the contact details at the top of this letter quoting the appropriate reference number.

If you are not content with the outcome your review, you do have the right of complaint to the Information Commissioner as established by section 50 of the Freedom of Information Act 2000. Generally, the Information Commissioner cannot make a decision unless you have exhausted the ICB's complaints procedure.

The Information Commissioner can be contacted at Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF or www.ico.org.uk.

Any information we provide following your request under the Freedom of Information Act will not confer an automatic right for you to re-use that information, for example to publish it. If you wish to re-use the information that we provide and you do not specify this in your initial application for information then you must make a further request for its re-use as per the Re-Use of Public Sector Information Regulations 2015 www.legislation.gov.uk. This will not affect your initial information request.

Yours faithfully

Information Governance Support Officer
North East and North Cumbria Integrated Care Board